Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488233 | 0.90 | TUBB4A (0.45) | HDAC6HDAC1FAAHACKR3CA12 | |
| SCHEMBL6500742 | 0.90 | HDAC1 (0.43) | HDAC6HDAC1ACKR3CA12CA1 | |
| SCHEMBL6487886 | 0.89 | HDAC1 (0.49) | HDAC6HDAC1FAAHACKR3NPC1 | |
| SCHEMBL6501328 | 0.89 | ACKR3 (0.47) | HDAC6HDAC1FAAHACKR3CA12 | |
| SCHEMBL6498684 | 0.89 | HDAC1 (0.43) | HDAC6HDAC1ACKR3CA12CA1 | |
| SCHEMBL6502456 | 0.89 | CA12 (0.42) | HDAC6HDAC1FAAHACKR3CA12 | |
| SCHEMBL6491167 | 0.89 | USP30 (0.48) | HDAC6HDAC1ACKR3CA12CA1 | |
| SCHEMBL6494428 | 0.87 | KMT2A (0.43) | HDAC6HDAC1ACKR3CA12CA1 | |
| SCHEMBL7225006 | 0.85 | ALDH1A1 (0.50) | HDAC6HDAC1POLBALDH1A1CHRNA7 | |
| SCHEMBL6496098 | 0.85 | ALDH1A1 (0.52) | POLBNPC1RAB9AALDH1A1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | claimed |
| EP-1442041-A1 | AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-04 | — | — | EP | claimed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | claimed |
| WO-2003040147-A1 | AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE__________________________________________________________________________________________________________________________ | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-15 | — | — | WO | claimed |
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1442041-A1 | AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
| WO-2003040147-A1 | AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE__________________________________________________________________________________________________________________________ | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | MALT1, WFS1, NR5A1 | HDAC6 1069/4885HDAC1 467/4885FAAH 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.